Glenmark Pharmaceuticals stock (INE935A01035): shares under pressure on NSE India as investors track valuation metrics

Glenmark Pharmaceuticals shares traded lower on the National Stock Exchange of India on 05/29/2026 amid a weaker Indian healthcare sector backdrop, putting the focus on how the stock is valued after the company’s recent operational updates.

Glenmark Pharmaceuticals shares came under pressure in India on 05/29/2026, trading lower on the National Stock Exchange of India (NSE) alongside a softer tone in the country’s healthcare names as investors reassessed risk across the sector.

According to the latest quote data from the National Stock Exchange of India, the stock trades under the ticker GLENMARK with ISIN INE935A01035, giving it a place in the Indian pharmaceuticals and healthcare space that is closely watched by domestic institutional and retail investors alike.

The move in the share price on 05/29/2026 follows a period in which Glenmark Pharmaceuticals has continued to feature in Indian equity market news flow, with traders monitoring not just underlying fundamentals but also derivatives metrics such as the put-call ratio on GLENMARK options, which are widely tracked as a gauge of market sentiment around the stock.

On the derivatives side, services such as NiftyInvest report put-call ratio and open interest data for GLENMARK, which some market participants use to interpret whether options markets are positioning more defensively or more constructively toward the shares at a given point in time.

While the broader BSE Healthcare index has also experienced sessions of notable downside in 2026, with individual days seeing declines of around 2.9 percent for the index and sharper single-stock moves such as a 5 percent fall in Glenmark Pharma shares on one of those dates, the current session on 05/29/2026 continues to highlight how sector-wide trends can amplify stock-specific volatility in India’s equity markets.

In the Indian home market context, Glenmark Pharmaceuticals is listed both on the NSE and BSE, and its performance is often benchmarked against the BSE Healthcare index and other domestic pharmaceutical peers, which means sharp moves in local healthcare indices can directly influence trading flows into and out of the stock.

For international investors tracking Glenmark Pharmaceuticals from Europe, the stock is also available on German trading venues such as Tradegate through secondary listings or over-the-counter trading lines, providing an additional route to access liquidity in the shares in euro terms even though the primary liquidity remains in Indian rupees on the NSE and BSE.

The stock’s current trading pattern comes after a series of operational and regulatory developments in recent years, including multiple product approvals in the United States and other markets, which have shaped how analysts and investors consider the medium-term earnings profile of the company.

On 05/29/2026, the price action underscores that despite these developments, Glenmark Pharmaceuticals remains sensitive to day-to-day changes in risk appetite toward Indian pharmaceutical stocks, as well as to shifts in expectations about future growth and margins that flow into valuation multiples.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Glenmark
• Sector/industry: Pharmaceuticals and generics
• Headquarters/country: Mumbai, India
• Core markets: India, United States, Europe and emerging markets
• Key revenue drivers: Branded generics in India and emerging markets, complex generics and specialty products in regulated markets such as the United States
• Home exchange/listing venue: National Stock Exchange of India (GLENMARK) and BSE India (GLENMARK)
• Trading currency: INR

Glenmark Pharmaceuticals: core business model

Glenmark Pharmaceuticals focuses on developing, manufacturing and marketing branded generics and specialty formulations across therapeutic areas such as dermatology, respiratory and oncology, with a business mix that combines its domestic India franchise with exports to regulated and emerging markets.

Valuation metrics and multiples for Glenmark Pharmaceuticals

With Glenmark Pharmaceuticals trading actively on the NSE India, valuation metrics such as price-to-earnings (P/E), enterprise value to EBITDA (EV/EBITDA) and price-to-book (P/B) ratios are central to how market participants interpret the current share price relative to the company’s earnings and asset base.

Data providers that track Glenmark Pharmaceuticals on the NSE regularly publish live and historical valuation indicators alongside the share price and volume, allowing investors to compare the company’s P/E and EV/EBITDA multiples with those of other Indian pharmaceutical peers and with broader market benchmarks, thereby framing whether the stock is trading at a discount or premium to the sector at any given time.

Conclusion

The weaker trading for Glenmark Pharmaceuticals shares on the NSE India on 05/29/2026 highlights how sentiment toward Indian healthcare stocks and derivatives positioning can influence short-term price action in this widely followed pharmaceutical name.

At the same time, the way the market values Glenmark Pharmaceuticals via metrics such as P/E and EV/EBITDA remains closely linked to expectations for its domestic and international branded generics and specialty businesses, which continue to be shaped by product approvals, competitive dynamics and regulatory developments.

Investors monitoring Glenmark Pharmaceuticals therefore tend to combine daily price movements and market sentiment signals with valuation multiples and company-specific news when forming a view on how the current share price compares with the company’s earnings and growth profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.